Stockscreener 앱 받기
4.41
5.50%
0.23
전일 마감가:
$4.18
열려 있는:
$4.16
하루 거래량:
804.03K
Relative Volume:
1.76
시가총액:
$307.87M
수익:
$63.39M
순이익/손실:
$-219.51M
주가수익비율:
-1.3942
EPS:
-3.1631
순현금흐름:
$-231.83M
1주 성능:
+1.38%
1개월 성능:
+9.43%
6개월 성능:
-33.58%
1년 성능:
-45.49%
1일 변동 폭
$4.075
$4.445
1주일 범위
$4.075
$4.515
52주 변동 폭
$3.92
$9.1592
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
명칭
Bicycle Therapeutics Plc Adr
전화
011441223261503
주소
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Compare BCYC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
4.41 | 307.87M | 63.39M | -219.51M | -231.83M | -3.1631 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Hold |
| 2025-10-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-08 | 개시 | Stephens | Equal-Weight |
| 2024-09-06 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-07 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-09-11 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2022-08-31 | 개시 | Cowen | Outperform |
| 2022-07-28 | 개시 | Barclays | Overweight |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-04-13 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2022-04-07 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-02-14 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | SVB Leerink | Outperform |
| 2021-12-09 | 개시 | Needham | Buy |
| 2021-09-30 | 개시 | B. Riley Securities | Buy |
| 2021-04-20 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-06-12 | 개시 | Oppenheimer | Outperform |
| 2020-04-17 | 개시 | H.C. Wainwright | Buy |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-09-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-06-17 | 개시 | Canaccord Genuity | Buy |
| 2019-06-17 | 개시 | Goldman | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
| 2019-06-17 | 개시 | Piper Jaffray | Overweight |
모두보기
Bicycle Therapeutics Plc Adr 주식(BCYC)의 최신 뉴스
Tarsus Pharmaceuticals (TARS) moves 7.5% higher: Will this strength last? - MSN
Price to earnings forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
Enterprise value to EBIT forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
Bicycle Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:BCYC) - TradingView
Price to sales forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
50BA Forecast — Price Target — Prediction for 2027 - TradingView
Bicycle Therapeutics shareholders approve all proposals at annual general meeting - Investing.com South Africa
BCYC - Finviz
Bicycle Therapeutics’ SWOT analysis: stock navigates trial delays - Investing.com
After plunging 20.2% in 4 weeks, here's why the trend might reverse for Bicycle Therapeutics (BCYC) - MSN
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Sees Significant Increase in Short Interest - MarketBeat
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - ChartMill
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Bicycle Therapeutics (BCYC) loses 19.0% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Bicycle Therapeutics (BCYC) schedules 2026 AGM with director, pay and auditor votes - Stock Titan
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - GlobeNewswire Inc.
Bicycle Therapeutics doses first patient in pancreatic cancer trial By Investing.com - Investing.com South Africa
Bicycle Therapeutics doses first patient in pancreatic cancer trial - Investing.com
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade - Yahoo Finance
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares of Stock - MarketBeat
Bicycle Therapeutics plc (BCYC) stock price, news, quote and history - Yahoo Finance UK
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Bicycle Therapeutics (BCYC) proxy: June 17 AGM, board and pay votes (BCYC) - Stock Titan
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC) - Yahoo Finance
Bicycle Therapeutics (BCYC) Drops 19.0% Over the Past 4 Weeks, Reasons a Potential Turnaround Could Be Near - Bitget
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Bicycle Therapeutics (NASDAQ:BCYC) Given New $15.00 Price Target at Needham & Company LLC - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Given New $36.00 Price Target at Oppenheimer - Defense World
Bicycle Therapeutics stock price target lowered to $7 by RBC Capital - Investing.com South Africa
Citizens cuts Bicycle Therapeutics stock price target on strategic shift By Investing.com - Investing.com South Africa
Bicycle Therapeutics (BCYC) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Truist cuts Bicycle Therapeutics stock price target on pipeline shift By Investing.com - Investing.com South Africa
Morgan Stanley reiterates Bicycle Therapeutics stock rating on program shift By Investing.com - Investing.com India
Morgan Stanley reiterates Bicycle Therapeutics stock rating on program shift - Investing.com
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
SUNation Energy Inc. (NASDAQ:SUNE) Short Interest Update - Defense World
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of “Buy” from Brokerages - Defense World
Bicycle Therapeutics Plc Adr (BCYC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):